Loading
A phase 2/3 trial of an investigational treatment in prostate cancer, run by Five Eleven Pharma, Inc., now recruiting.
PSMA-PET to Guide Prostatectomy is a phase 2/3 interventional study registered as NCT05381103 by Five Eleven Pharma, Inc., with 288 participants planned, started 2021-10-01 and due to reach its primary completion in 2028-06-01.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares PET (positron emission tomography), Prostate cancer and the tag pipeline.
Shares PSMA, Prostate cancer and the tag pipeline.
Shares PSMA, Prostate cancer and the tag pipeline.
Shares PSMA, Prostate cancer and the tag pipeline.
Shares PET (positron emission tomography), Prostate cancer and the tag pipeline.
Shares PET (positron emission tomography), PSMA, Prostate cancer and the tag pipeline.
Shares PET (positron emission tomography), Prostate cancer and the tag pipeline.
Shares PET (positron emission tomography) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/